MedTrace Logo

DIabetes REsearCh on Patient sTratification (DIRECT): GLP-1R Agonists

NCT01575301 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 411

Last updated 2018-04-11

No results posted yet for this study

Summary

The purpose of this study is to collect a cohort of patients treated with GLP-1R Agonists and to assess phenotypic, genetic and genomic biomarkers of glycaemic response to these agents.

Conditions

Interventions

DRUG

Exenatide, Liraglutide

Dosage, frequency and duration not specified by protocol

Sponsors & Collaborators

  • Newcastle-upon-Tyne Hospitals NHS Trust

    collaborator OTHER

  • Oxford University Hospitals NHS Trust

    collaborator OTHER

  • Royal Devon and Exeter NHS Foundation Trust

    collaborator OTHER

  • University of Dundee

    lead OTHER

Principal Investigators

  • Ewan Pearson · University of Dundee

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2015-07-31
Completion
2015-12-11

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01575301 on ClinicalTrials.gov